Zacks Research Estimates Alkermes FY2027 Earnings

Alkermes plc (NASDAQ:ALKS) – Equities research analysts at Zacks Research issued their FY2027 EPS estimates for shares of Alkermes in a research report issued on Wednesday, March 5th. Zacks Research analyst R. Department anticipates that the company will post earnings of $1.15 per share for the year. The consensus estimate for Alkermes’ current full-year earnings is $1.31 per share.

Other analysts have also issued reports about the stock. HC Wainwright reissued a “neutral” rating and set a $46.00 target price on shares of Alkermes in a research note on Thursday, February 13th. The Goldman Sachs Group upped their target price on shares of Alkermes from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. UBS Group raised shares of Alkermes from a “sell” rating to a “neutral” rating and lifted their price target for the company from $21.00 to $38.00 in a research note on Tuesday. Mizuho increased their price objective on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research note on Wednesday, November 13th. Finally, StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 13th. Three analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.33.

Alkermes Trading Down 0.3 %

ALKS stock opened at $35.28 on Thursday. The company has a 50-day moving average price of $31.66 and a 200 day moving average price of $29.55. Alkermes has a 12 month low of $22.90 and a 12 month high of $36.45. The stock has a market cap of $5.74 billion, a PE ratio of 16.26, a P/E/G ratio of 2.20 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a net margin of 23.57% and a return on equity of 30.80%.

Insider Buying and Selling

In other news, Director Cato T. Laurencin sold 2,691 shares of the stock in a transaction on Monday, December 9th. The shares were sold at an average price of $31.85, for a total value of $85,708.35. Following the sale, the director now owns 23,013 shares in the company, valued at $732,964.05. This represents a 10.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Craig C. Hopkinson sold 144,419 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the transaction, the executive vice president now directly owns 57,875 shares of the company’s stock, valued at approximately $2,056,298.75. This trade represents a 71.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 309,179 shares of company stock worth $10,412,450 in the last three months. Corporate insiders own 4.89% of the company’s stock.

Institutional Trading of Alkermes

Several hedge funds and other institutional investors have recently bought and sold shares of ALKS. Wealth Enhancement Advisory Services LLC acquired a new position in shares of Alkermes in the 3rd quarter valued at $281,000. New York State Teachers Retirement System boosted its stake in shares of Alkermes by 14.3% during the 3rd quarter. New York State Teachers Retirement System now owns 90,111 shares of the company’s stock worth $2,522,000 after acquiring an additional 11,289 shares in the last quarter. US Bancorp DE grew its position in shares of Alkermes by 48.8% during the 3rd quarter. US Bancorp DE now owns 10,302 shares of the company’s stock valued at $288,000 after acquiring an additional 3,378 shares during the period. Van ECK Associates Corp grew its position in shares of Alkermes by 40.0% during the 3rd quarter. Van ECK Associates Corp now owns 104,986 shares of the company’s stock valued at $2,924,000 after acquiring an additional 29,998 shares during the period. Finally, Robeco Institutional Asset Management B.V. increased its stake in shares of Alkermes by 92.4% in the 3rd quarter. Robeco Institutional Asset Management B.V. now owns 95,509 shares of the company’s stock valued at $2,673,000 after purchasing an additional 45,857 shares in the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.